Founded in March this year, Orion Medical, based in Cham, Switzerland, has been established as a specialist in 3D printing for the medical devices industry. The company is closely linked to Orion Additive Manufacturing (Orion AM), an established manufacturer of 3D printing systems for high-performance polymers based in Berlin, Germany.
Owen Mumford, a global leader specialised in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech and generics industries, has signed an exclusive agreement with Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions for the Aidaptus auto-injector.
The agreement makes Stevanato Group an exclusive manufacturing partner for the Owen Mumford designed auto-injector, offering a full set of capabilities to its pharmaceutical customers. Stevanato Group will mould the components for Aidaptus and provide final and sub-assembly equipment, while also offering market-leading pre-filled syringes to enable pharmaceutical customers to create the final product for patient use. Assembly of the components will be undertaken by both Stevanato Group at its global manufacturing sites and by Owen Mumford at its automated assembly centre of excellence in the UK.
The collaboration is intended to bring added value to customers, matching world-class device expertise with premium manufacturing capabilities. It is expected to streamline device production and deliver the full value of the innovative Aidaptus platform to the market.
Aidaptus is a 2-step, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features plunger sensing technology with a self-adjusting plunger rod that automatically adapts to the individual plunger positions and different fill volumes in each syringe, with no change parts required. The auto-injector is also able to accommodate a unique variety of drug viscosities.
“Aidaptus will help patients to self-administer their individual therapies using a simple and easy to use device,” said Adam Mumford, Director of Owen Mumford. “At the same time, this auto-injector can help to reduce complexity, minimise supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes. Often during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well.”
Mauro Stocchi, Chief Business Officer of Stevanato Group, commented: “We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market. As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors. With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems.”
Steven Kaufman, VP for Drug Delivery Systems at Stevanato Group, added: “The Aidaptus auto-injector platform combines ease of use for patients with faster time-to-market access for pharma organisations. We aim to be the strategic partner with which to develop innovative combination products as we continue the expansion of our integrated capabilities in the drug delivery space, and for this reason we are very excited to work with Owen Mumford and provide access to its exciting new auto-injector platform.”
Ixaka, an integrated cell and gene therapy company, says that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product.
Olympus Corporation has completed the separation of its Scientific Solutions business to a wholly-owned subsidiary, Evident Corporation. Following the divestiture of its Imaging business, this move further signifies the company’s long-term strategy to cement its position as a major player in the medtech industry.
Vygon, a specialist single-use medical devices group, has acquired Macatt Medica, a distribution company located in Lima, Peru. The company distributes the majority of Vygon’s products in Peru, including a wide range of enteral nutrition products. The financial terms of the agreement have not been disclosed.
Registration is now open for the International Hospital Federation’s 45th World Hospital Congress, taking place on 9–11 November 2022 at the Dubai International Convention & Exhibition Centre (DWTC), UAE.
Headaches such as migraine are among the leading causes of morbidity worldwide, but most treatments provide only partial relief. While scientists know that migraine and related headaches are caused by activity in a part of the nervous system known as the trigeminal ganglion (TG), it remains unclear which genes and cell types of the TG are […]
Mayo Clinic researchers have proposed a new model for mapping the symptoms of Alzheimer’s disease to brain anatomy. This model was developed by applying machine learning to patient brain imaging data. It uses the entire function of the brain rather than specific brain regions or networks to explain the relationship between brain anatomy and mental […]
French company CardioRenal, which specializes in improving treatment at home for patients with severe chronic kidney disease, has secured €3.3 million from business angels and longstanding company shareholders as part of a round of seed capital financing.
Medical equipment made using Solvay’s Udel high-performance polysulfone (PSU) thermoplastic will be recycled at the end of their useful lives in a new sustainability initiative that the company has embarked on with Mitsubishi Chemical Advanced Materials (MCAM).
April 2024
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.